MaRS Innovation Announces Collaboration with Johnson & Johnson Innovation to Advance Early-Stage Technologies Related to Human Health
TORONTO, Nov. 25, 2013 /CNW/ - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly identify and fund high-potential opportunities emerging from well-validated scientific research discoveries within MaRS Innovation's 16 member institutions, which include the University of Toronto and its affiliated teaching hospitals.
"We are looking forward to working with Johnson & Johnson Innovation," said Dr. Raphael Hofstein, president and CEO, MaRS Innovation. "There are many high quality opportunities coming out of the Toronto research community, and these opportunities can benefit from our close collaboration."
Through the agreement, Johnson & Johnson Innovation will provide funding over a three-year period to support promising individual projects based on joint due diligence, which will be leveraged with financial support from MaRS Innovation.
The fund will accelerate the development and validation of healthcare technologies within one of Canada's highly innovative academic clusters.
About MaRS Innovation
MaRS Innovation is the commercialization agent for Ontario's exceptional discovery pipeline from 16 leading academic institutions. As a single-entry point to member-based activity of $1 billion in annual research and development, MI is a gateway for investors and licensees to access technology assets. Supported by the Government of Canada through the Networks of Centres of Excellence, by the Government of Ontario through the Ontario Centres of Excellence, and by its 16 member institutions, MI is a transformational partnership that turns research strengths into commercial opportunities. MI's portfolio includes the most promising assets from its members' pipeline, which it advances into global markets through industry partnerships, licensing and company creation.
SOURCE MaRS Innovation
Image with caption: "MaRS Innovation, based in Toronto, Canada, is the commercialization agent for Ontario's exceptional discovery pipeline from 16 leading academic institutions. (CNW Group/MaRS Innovation)". Image available at: http://photos.newswire.ca/images/download/20131125_C4596_PHOTO_EN_33794.jpgFor further information:
Marketing and Communications Manager
647-260-7850 / @marsinnovation / @wavecheckyellow